Cellular replacement therapy for Parkinson's disease - Where we are today?

Neuroscientist

Volumn 8, Issue 5, 2002, Pages 457-488

  Redmond Jr , D Eugene ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Fetal neural transplantation; Human primate stem cell; Parkinson's

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; LEVODOPA;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CADAVER; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOUBLE BLIND PROCEDURE; DYSKINESIA; ELECTRON MICROSCOPY; FETAL NEURAL TRANSPLANTATION; GRAFT SURVIVAL; HUMAN; MESENCEPHALON; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINAL CORD INJURY; STEM CELL; VASCULARIZATION;

EID: 0036788844     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385802237703     Document Type: Review

References (333)

1. Abbott A. 2001. Trials offer way forward for Parkinson's. Nature 410(6827):401.
2. Abrous N, Gui J, Vigny A, Calas M, LeMoal M, Herman J. 1988. Development of intracerebral dopaminergic grafts: a combined immunohistochemical and autoradiographic study of its time course and environmental influences. J Comp Neurol 273:26-41.
3. Aebischer P, Ridet J. 2001. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci 24(9):533-40.
4. Ahlskog JE. 1990. Parkinson's disease: new treatment strategies [Review]. Comp Ther 16(12):41-6.
5. Annett LE, Martel FL, Rogers DC, Ridley RM, Baker HF, Dunnett SB. 1994. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 125(2):228-46.
6. Antman K, Lagakos S, Drazen J. 2001. Designing and funding clinical trials of novel therapies. N Engl J Med 344(10):762-3.
7. Arenas E. 2002. Stem cells in the treatment of Parkinson's disease. Brain Res Bull 57(6):795-808.
8. Backlund EO, Granberg B, Hamberger E, Knutsson A, Mårtensson G, Sedvall G, and others. 1985. Transplantation of adrenal medullary tissue to striatum in parkinsonism: first clinical trials. J Neurosurg 62:169-73.
9. Bacopoulos NG, Maas JW, Hattox SE, Roth RH. 1978. Regional distribution of dopamine metabolites in human and primate brain. Comm Psychopharmacol 2:281-6.
10. Bakay RA. 2001. Is transplantation to treat Parkinson's disease dead? Neurosurgery 49(3):576-80.
11. Bakay RAE, Barrow DL, Fiandaca MS, Iuvone PM, Schiff A, Collins DC. 1987. Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation. Ann N Y Acad Sci 495:623-40.
12. Baker KA, Sadi D, Hong M, Mendez I. 2000. Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft. J Comp Neurol 426(1):106-16.
13. Barker RA, Dunnett SB, Faissner A, Fawcett JW. 1996. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp Neurol 141(1):79-93.
14. Bergman H, Raz A, Feingold A, Nini A, Nelken I, Hansel D, and others. 1998. Physiology of MPTP Tremor. Mov Disord 13:29-34.
15. Bjorklund A. 1993. Neurobiology. Better cells for brain repair [news; comment]. Nature 362(6419):414-5.
16. Bjorklund A. 2000. Cell replacement strategies for neurodegenerative disorders. Novartis Found Symp 231:7-15.
17. Björklund A, Dunnet SB, Stenevi U, Lewis ME, Iverson SD. 1980. Reinnervation of the denervated striatum by substantia nigra transplants. Functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 199:307-33.
18. Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. 2000. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886(1-2):82-98.
19. Bjorklund A, Stenevi U. 1979. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177(3):555-60.
20. Bjorklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. 1983. Intracerebral grafting of neuronal cell suspensions: II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol Scand Suppl 522:9-18.
21. Bjorklund A, Stenevi U, Svendgaard N. 1976. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature 262(5571):787-90.
22. Bjorklund L, Spenger C, Stromberg I. 1997. Tirilazad mesylate increases dopaminergic neuronal survival in the in oculo grafting model. Exp Neurol 148:324-33.
23. Bjorklund L, Vidal N, Stromberg I. 1998. Lazaroid-enhanced survival of grafted dopamine neurons does not increase target innervation. Neuroreport 9:2815-19.
24. Bohn MC, Connor B, Kozlowski DA, Mohajeri MH. 2000. Gene transfer for neuroprotection in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Novartis Found Symp 231:70-89.
25. Boonman Z, Isacson O. 1999. Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Exp Neurol 156(1):1-15.
26. Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, and others. 1996. CNS immunological modulation of neural graft rejection and survival. Neurol Res 18(4):297-304.
27. Bredesen D. 1995. Neural apoptosis. Ann Neurol 38:839-51.
28. Breeze RE, Wells TH Jr, Freed CR. 1995. Implantation of fetal tissue for the management of Parkinson's disease: a technical note. Neurosurgery 36(5):1044-7; discussion 1047-8.
29. Breier G, Albrecht U, Sterrer S, Risau W. 1992. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521-32.
30. Brevig T, Meyer M, Kristensen T, Zimmer J. 2001. Neural xenotransplantation: pretreatment of porcine embryonic nigral tissue with anti-Gal antibodies and complement is not toxic for the dopaminergic neurons. Cell Transplant 10(1):25-30.
31. Broadwell R, Chalton H, Ebert P, Hickey W, Shirazi Y, Villegas J, and others. 1991. Allografts of CNS tissue possess a blood-brain barrier: II. Angiogenesis in solid tissue and cell suspension graft. Exp Neurol 112:1-28.
32. Broadwell R, Charlton H, Balin B, Salcman M. 1987. Angioarchitecture of the CNS, pituitary gland, and intracerebral grafts revealed with peroxidase cytochemistry. J Comp Neurol 260:47-62.
33. Brundin P, Barbin G, Isacson O, Mallat M, Chamak B, Prochiantz A, and others. 1985. Survival of intracerebrally grafted rat dopamine neurons previously cultured in vitro. Neurosci Lett 61(1-2):79-84.
34. Brundin P, Bjorklund A, Lindvall O. 1990. Practical aspects of the use of human fetal brain tissue for intracerebral grafting [Review]. Prog Brain Res 82:707-14.
35. Brundin P, Dunnett S, Bjorklund A, Nikkhah G. 2001. Transplanted dopaminergic neurons: more or less? Nat Med 7(5):512-3.
36. Brundin P, Isacson O, Bjorklund A. 1985. Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res 331(2):251-9.
37. Brundin P, Isacson O, Gage FH, Bjorklund A. 1986. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target or non-target cells. Brain Res 389(1-2):77-84.
38. Brundin P, Karlsson J, Emgard M, Schierle GS, Hansson O, Petersen A, and others. 2000. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 9(2):179-95.
39. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A and others. 2000. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123(Pt 7):1380-90.
40. Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, and others. 1988. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 70:192-208.
41. Bundock EA, Blanchard B, Evans L, Elsworth JD, Roth RH, Redmond DE Jr, and others. 1998. Neurogenesis of the substantia nigra in the non-human primate. Am Soc Neural Transplant Rep 4:53.
42. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80(14):4546-50.
43. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. 1985. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 312(22):1418-21.
44. Buttke T, Sandstrom P. 1994. Oxidative stress as a mediator of apoptosis. Immunol Today 15:7-10.
45. CAPIT Committee, Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, and others. 1992. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov Disord 7:2-13.
46. Carney JM, Starke-Reed PE, Oliver CN, Landum RW, Cheng MS, Wu JF, and others. 1991. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci U S A 88(9):3633-6.
47. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, and others. 1997. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochimica et Biophysica Acta 1362(1):77-86.
48. Catapano LA, Sheen VL, Leavitt BR, Macklis JD. 1999. Differentiation of transplanted neural precursors varies regionally in adults striatum. Neuroreport 10(18):3971-7.
49. Cattaneo E, McKay R. 1990. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature 347(6295):762-5.
50. Chauhan NB, Siegel GJ, Lee JM. 2001. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 21(4):277-88.
51. Chiang Y, Morales M, Zhou FC, Borlongan C, Hoffer BJ, Wang Y. 2001. Fetal intra-nigral ventral mesencephalon and kidney tissue bridge transplantation restores the nigrostriatal dopamine pathway in hemi-parkinsonian rats. Brain Res 889(1-2):200-7.
52. Chiueh C, Markey SP, Burns RS, Johannsen J, Pert A, Kopin IJ. 1984. Neurochemical and behavioral effects of systemic and intranigral administration of n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 100:189-94.
53. Choi-Lundberg D, Bohn M. 1995. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Devel. Brain Res 85:80-8.
54. Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, and others. 1997. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275(5301):838-41.
55. Clark W, Hazel J, Coull B. 1995. Lazaroids. CNS pharmacology and current research. Drugs 50:971-83.
56. Clarke PGH. 1999. Apoptosis versus necrosis: how valid a dichotomy for neurons? In: Koliatsos VE, Ratan RR, Choi D, editors. Cell death and diseases of the nervous system. Totowa (NJ): Humana Press. p 3-28.
57. Clarkson ED, Zawada WM, Bell KP, Esplen JE, Choi PK, Heidenreich KA, and others. 2001. IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands. Exp Neurol 168(1):183-91.
58. Clarkson ED, Zawada WM, Freed CR. 1995. GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport 7(1):145-9.
59. Clarkson ED, Zawada WM, Freed CR. 1997. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res 289(2):207-10.
60. Clayton G, Thomas H, Mahalik J, Finger T. 1991. GAP-43 and 5B4 immunoreactivity during the development of fetal mesencephalic neurons. Exp Neurol 114:1-10.
61. Cohen J. 1994. New fight over fetal tissue grafts. Science 263:600-1.
62. Collier T, Sortwell C. 1999. Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14:261-87.
63. Collier TJ, Sortwell CE, Daley BF. 1999. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 19(13):5563-73.
64. Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek JR Jr, and others. 2002. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. J Comp Neurol 442:320-30.
65. Costantini LC, Vozza BM, Snyder-Keller AM. 1994. Enhanced efficacy of nigral-striatal cotransplants in bilaterally dopamine-depleted rats: an anatomical and behavioral analysis. Exp Neurol 127(2):219-31.
66. Craven R. 2001. Disappointment for Parkinson's disease patients. Trends Pharmacol Sci 22(5):221.
67. Daadi MM, Weiss S. 1999. Generation of tyrosine hydroxylaseproducing neurons from precursors of the embryonic and adult forebrain. J Neurosci 19(11):4484-97.
68. Daguet MC, Di Porzio U, Prochiantz A, Kato A, Glowinski J. 1980. Release of dopamine from dissociated mesencephalic dopaminergic neurons in primary cultures in absence or presence of striatal target cells. Brain Res 191(2):564-8.
69. Dal Toso R, Giorgi O, Soranzo C, Kirschner G, Ferrari G, Favaron M, and others. 1988. Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNF). J Neurosci 8(3):733-45.
70. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. 2001. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293(5532): 1164-6.
71. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, and others. 1997. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Med 3(3):350-3.
72. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, and others. 1996. Long-term outcome of unilaterally transplanted parkinsonian patients: I. Clinical approach. Brain 119(Pt 1):41-50.
73. Deglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, Aebischer P. 1996. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum Gene Ther 7(17):2135-46.
74. Deutch AY, Elsworth JD, Goldstein M, Fuxe K, Redmond DE Jr, Sladek JR Jr, and others. 1986. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4phenyl- 1,2,3,6-tetrahydropyridine. Neurosci Lett 68(1):51-6.
75. Dong JF, Detta A, Bakker MH, Hitchcock ER. 1993. Direct interaction with target-derived glia enhances survival but not differentiation of human fetal mesencephalic dopaminergic neurons. Neuroscience 56(1):53-60.
76. Duan WM, Widner H, Frodl EM, Brundin P. 1995. Immune reactions following systemic immunization prior or subsequent to intrastriatal transplantation of allogeneic mesencephalic tissue in adult rats. Neuroscience 64(3):629-41.
77. Dunn EH. 1917. Primary and secondary findings in a series of attempts to transplant cerebral cortex in the albino rat. J Comp Neurol 27:565-82.
78. Dunnett SB, Bjorklund A, Lindvall O. 2001. Cell therapy in Parkinson's disease-stop or go? Nat Rev Neurosci 2(5):365-9.
79. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD. 1983. Intracerebral grafting of neuronal cell suspension: IV. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions in different brain sites. Acta Phys Scand Suppl 522:39-47.
80. Dunnett SB, Rogers DC, Richards SJ. 1989. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal "bridge" grafts. Exp Brain Res 75(3):523-35.
81. Dunnett SB, Whishaw IQ, Rogers DC, Jones GH. 1987. Dopaminerich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with hydroxydopamine lesions. Brain Res 415:63-78.
82. Dusart I, Nothias F, Roudier F, Besson J, Peschanski M. 1989. Vascularization of fetal cell suspension grafts in the excitotoxically lesioned adult rat thalamus. Dev Brain Res 48:215-28.
83. Editorial. 2001. Prospects for Parkinson disease. Nat Med 7(4):381.
84. Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH. 1987a. Differential responsiveness to 1-methyl-4-phenyl- 1,2,3,6tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sci 40(2):193-202.
85. Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH. 1987b. Effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) on catecholamine and metabolites in primate brain and CSF. Brain Res 415:293-9.
86. Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, and others. 1991. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther 259:595-600.
87. Emerich DF, Winn SR, Christenson L, Palmatier MA, Gentile FT, Sanberg PR. 1992. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy [Review]. Neurosci Biobehav Rev 16(4):437-47.
88. Fahn S, Elton R, Committee amotUD. 1987. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Goldstein M, Calne C, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan. p 153-63.
89. Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, and others. 2000. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A 97(26):14686-91.
90. Felten DL, Sladek JRJ. 1983. Monoamine distribution in primate brain V. monoamine nuclei: anatomy, pathways and local organization. Brain Res Bull 10:171-284.
91. Ferrer I, Tortosa A, Macaya A, Sierra A, Moreno D, Munell F, and others. 1994. Evidence of nuclear DNA fragmentation following hypoxia-ischemia in the infant rat brain, and transient forebrain ischemia in the adult gerbil. Brain Pathol 4:115-22.
92. Fischbach GD, McKhann GM. 2001. Cell therapy for Parkinson's disease. N Engl J Med 344(10):763-5.
93. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. 1991. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6(3):371-80.
94. Fisher LJ, Young SJ, Tepper JM, Groves PM, Gage FH. 1991. Electrophysiological characteristics of cells within mesencephalon suspension grafts. Neuroscience 40(1):109-22.
95. Flax JD, Aurora S, Yang C, Simonin C, Wills AM, Billinghurst LL, and others. 1998. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 16(11):1033-9.
96. Foellmer HG, Taylor JR, Elsworth JD, Redmond DE Jr. 1998. Vitrification of brain tissue for transplantation. Neurosci Abstr 24:1302(517.7).
97. Folkerth RD, Durso R. 1996. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 46(5):1219-25.
98. Forno LS, DeLanney LE, Irwin I, Langston JW. 1986. Neuropathology of MPTP-treated monkeys: comparison with the neuropathology of human idiopathic Parkinson's disease. In: Markey SP, editor. MPTP: a neurotoxin producing a parkinsonian syndrome. Orlando (FL): Academic Press. p 119-40.
99. Freed C, Breeze R, Bjugstad KB, Greene JG, Tsai WY, Trojanowski JQ, and others. 2001. Long term follow-up of human embryonic dopamine cell transplants in advanced Parkinson's disease. Am Soc Neural Transplant Rep 8:36.
100. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi J, and others. 1992. Survival of implanted dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 327:1549-55.
101. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, and others. 1990. Transplantation of human fetal dopamine cells for Parkinson's disease: results at I year. Arch Neurol 47:505-12.
102. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, and others. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344(10):710-9.
103. Freed WJ, Morihisa JM, Spoor E, Hoffer BJ, Olson L, Seiger A, and others. 1981. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 292:351-2.
104. Freeman TB, Sanberg PR, Isacson O. 1995. Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Cell Transplant 4(6):539-45.
105. Freeman TB, Spence MS, Boss BD, Spector DH, Strecker RE, Olanow CW, and others. 1991. Development of dopaminergic neurons in the human substantia nigra. Exp Neurol 113:344-53.
106. Freund TF, Bolam JP, Björklund A, Stenevi U, Dunnet SB, Powel JF, and others. 1985. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host striatum: a tyrosine hydroxlase immuncytochemical study. J Neurosci 5:603-16.
107. Friedrich MJ. 1999. Fetal pig neural cells for Parkinson disease. JAMA 282(23):2198-9.
108. Gage FH, Fisher LJ, Jinnah HA, Rosenberg MB, Tuszynski MH, Friedmann T. 1990. Grafting genetically modified cells to the brain: conceptual and technical issues [Review]. Prog Brain Res 82:1-10.
109. Gage FH, Ray J, Fisher LJ. 1995. Isolation, characterization, and use of stem cells from the CNS. [Review]. Ann Rev Neurosci 18:159-92.
110. Garrick NA, Redmond DE Jr, Murphy DL. 1979. Primate-rodent monoamine oxidase differences. In: Singer TP, Von Korff RW, Murphy DL, editors. Monoamine oxidase: structure, function, and altered functions. New York: Academic Press. p 351-9.
111. Garver D, Sladek JR Jr. 1975. Monoamine distribution in primate brain: I. Catecholamine-containing perikarya in the brain stem of Macaca speciosa. J Comp Neurol 159:289-303.
112. Gates MA, Fillmore H, Steindler DA. 1996. Chondroitin sulfate proteoglycan and tenascin in the wounded adult mouse neostriatum in vitro: dopamine neuron attachment and process outgrowth. J Neurosci 16(24):8005-18.
113. Gjedde A, Reith J, Dyve S, Léger G, Guttman M, Diksic M, and others. 1991. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A 88:2721-5.
114. Glover V, Sandler M, Owen F, Riley GJ. 1977. Dopamine is a monoamine oxidase B substrate in man. Nature 265:80-1.
115. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, and others. 1989. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 320:337-42.
116. Granholm AC, Mott JL, Bowenkamp K, Eken S, Henry S, Hoffer BJ, and others. 1997. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 116(1):29-38.
117. Gritti A, Vescovi AL, Galli R. 2002. Adult neural stem cells: plasticity and developmental potential. J Physiol Paris 96(1-2):81-90.
118. Gultekin F, Delibas N, Yasar S, Kilinc I. 2001. In vivo changes in antioxidant systems and protective role of melatonin and a combination of vitamin C and vitamin E on oxidative damage in erythrocytes induced by chlorpyrifos-ethyl in rats. Arch Toxicol 75(2):88-96.
119. Hagell P, Crabb L, Pogarell O, Schrag A, Widner H, Brooks DJ, and others. 2000. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Mov Disord 15(2):224-9.
120. Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, and others. 2002. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5(7):627-8.
121. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, and others. 1999. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122(Pt 6):1121-32.
122. Hall E, McCall J, Means E. 1994. Therapeutic potential of the lazaroids (21-Aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemmorrhage. Adv Pharmacol 28:221-65.
123. Hallett M, Litvan I. 2000. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Task Force on Surgery for Parkinson's Disease of the American Academy of Neurology Therapeutic and Technology Assessment Committee. Mov Disord 15(3):436-8.
124. Hansson O, Castilho RF, Kaminski Schierle GS, Karlsson J, Nicotera P, Leist M, and others. 2000. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol 164(1):102-11.
125. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, and others. 1999. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56(2):179-87.
126. Haycock JW. 1991. Four forms of tyrosine hydroxylase are present in human adrenal medulla. J Neurochem 56:2139-42.
127. Helt CE, Hoernig GR, Albeck DS, Gerhardt GA, Ickes B, Reyland ME, and others. 2001. Neuroprotection of grafted neurons with a GDNF/caspase inhibitor cocktail. Exp Neurol 170(2):258-69.
128. Henderson BT, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. 1991. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 48(8):822-7.
129. Hill I, MacManus J, Rasquinha I, Tuor U. 1995. DNA fragmentation indicative of apoptosis following unilateral cerebral hypoxiaischemia in the neonatal rat. Brain Res 676:398-403.
130. Hitchcock E. 1994. Stereotactic neural transplantation [Review]. Stereotactic Function Neurosurg 62(1-4):120-33.
131. Hitchcock EH, Whitwell HL, Sofroniew M, Bankiewicz KS. 1994. Survival of TH-positive and neuromelanin-containing cells in patients with Parkinson's disease after intrastriatal grafting of fetal ventral mesencephalon. Exp Neurol 129:3.
132. Hitchcock ER, Clough C, Hughes RC, Kenny BG. 1988. Embryos and Parkinson's disease. Lancet i:1274.
133. Hitchcock ER, Kenny BG, Henderson BT, Clough CG, Hughes RC, Detta A. 1991. A series of experimental surgery for advanced Parkinson's disease by fetal mesencephalic transplantation. Acta Neurochirurgica Suppl 52:54-7.
134. Hoffer B, Seiger A, Freedman R, Olson L, Taylor D. 1977. Electrophysiology and cytology of hippocampal formation transplants in anterior chamber of the eye: II. Cholinergic mechanisms. Brain Res 119:107-32.
135. Hoffer BJ, Olson L. 1991. Ethical issues in brain-cell transplantation. Trends Neurosci 14:384-8.
136. Hoffer BJ, Seiger A, Ljungberg T, Olson L. 1974. Electrophysiological and cytological studies of brain homografts in the anterior chamber of the eye: maturation of cerebellar cortex in oculo. Brain Res 79:165-84.
137. Hoffmann PC, Hemmendinger LM, Kotake C, Heller A. 1983. Enhanced dopamine cell survival in reaggregates containing telencephalic target cells. Brain Res 274(2):275-81.
138. Hoshi H, Kuwabara H, Léger G, Cumming P, Guttman M, Gjedde A. 1993. 6-[18F]fluoro-L-DOPA metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57-69.
139. Isacson O, Bjorklund L, Pernaute RS. 2001. Parkinson's disease: interpretations of transplantation study are erroneous. Nat Neurosci 4(6):553.
140. Isacson O, Breakefield XO. 1997. Benefits and risks of hosting animal cells in the human brain [see comments] [Review]. Nature Med 3(9):964-9.
141. Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A. 1999. Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotact Funct Neurosurg 72(2-4):219-24.
142. Janec E, Burke R. 1993. Naturally occurring cell death during postnatal development of the substantia nigra pars compacta of rat. Molec. Cell Neurosci 4:30-5.
143. Karlsson J, Emgard M, Gido G, Wieloch T, Brundin P. 2000. Increased survival of embryonic nigral neurons when grafted to hypothermic rats. Neuroreport 11(8):1665-8.
144. Kaseloo PA, Lis A, Asada H, Barone TA, Plunkett RJ. 1996. In vitro assessment of neurotrophic activity from the striatum of aging rats. Neurosci Lett 218(3):157-60.
145. Kawaja MD, Rosenberg MB, Yoshida K, Gage FH. 1992. Somatic gene transfer of nerve growth factor promotes the survival of axotomized septal neurons and the regeneration of their axons in adult rats. J Neurosci 12(7):2849-64.
146. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, and others. 2002. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418(6893):50-6.
147. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, and others. 2001. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal dopamine system. J Neurosci 22(7):2780-91.
148. Kolata G. 2001. Parkinson's research is set back by failure of fetal cell implants. The New York Times, p A1.
149. Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL. 1996. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Cell Transplant 5(2):327-37.
150. Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL. 1997. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 146(2):536-45.
151. Kordower J, Freeman T, Snow B, Vingerhoets F, Mufson E, Sanberg P, and others. 1995. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332:1118-24.
152. Kordower J, Rosenstein J, Collier T, Burke M, Chen E-Y, Li J, and others. 1996. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ulturastructural, and metabolic studies. J Comp Neurol 370:203-30.
153. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, and others. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290(5492):767-73.
154. Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. 1997. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 6(3):213-9.
155. Korsmeyer S, Yin X-M, Oltvai N, Veis-Novack D, Linette G. 1995. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1271:63-6.
156. Krum J, Rosenstein J. 1988. Patterns of angiogenesis in neural transplant models: II. Fetal neocortical transplants. J Comp Neurol 271:331-45.
157. Kudoh C, Detta A, Meyer C, Byrne P, Hitchcock E. 1999. Bilateral intracaudate cografting of fetal ventral mesencephalon and striatum in advanced Parkinson's disease. Transplant Proc 31(8):3397-402.
158. Kuwabara H, Cumming P, Reith J, Léger G, Diksic M, Evans AC, and others. 1993. Human striatal L-DOPA decarboxylase activity estimated in vivo using 6-[18F]flouro-DOPA and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 13:1-14.
159. Lacorazza HD, Flax JD, Snyder EY, Jendoubi M. 1996. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nature Med 2(4):424-9.
160. Langston J, Irwin I, Langston E, Forno L. 1984. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48:87-92.
161. Langston JW, Forno LS, Rebert CS, and Irwin I. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292:390-4.
162. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598-605.
163. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, and others. 1992. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov Disord 7:2-13.
164. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. 2000. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 20(23):8604-9.
165. Leranth C, Sladek J Jr, Roth R, Redmond D Jr. 1998. Efferent synaptic connections of dopaminergic neurons grafted into the caudate nucleus of experimentally induced parkinsonian monkeys are different from those of control animals. Exp Brain Res 123:323-33.
166. Lim DA, Flames N, Collado L, Herrera DG. 2002. Investigating the use of primary adult subventricular zone neural precursor cells for neuronal replacement therapies. Brain Res Bull 57(6):759-64.
167. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments]. Science 260(5111):1130-2.
168. Lin LF, Zhang TJ, Collins F, Armes LG. 1994. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J Neurochem 63(2):758-68.
169. Lindvall O. 1989. Transplantation into the human brain: present status and future possibilities. J Neurol Neurosurg Psychiatry Spec June(Suppl):39-54.
170. Lindvall O. 1999. Cerebral implantation in movement disorders: state of the art. Mov Disord 14(2):201-5.
171. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, and others. 1990. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247:574-7.
172. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, and others. 1989. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 46:615-31.
173. Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, and others. 1988. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 2:1483-4.
174. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, and others. 1992. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31:155-65.
175. Ling ZD, Collier TJ, Sortwell CE, Lipton JW, Vu TQ, Robie HC, and others. 2000. Striatal trophic activity is reduced in the aged rat brain. Brain Res 856(1-2):301-9.
176. Lobianco C, Ridet JL, Zurn AD, Deglon N, Aebischer P. 2001. Dopaminergic cell loss induced by lentiviral-mediated overexpression of wild type or mutant human α-synuclein in the substantia nigra of rats. Soc Neurosci Abstr 27: 324.10.
177. Lopez-Lozano JJ, Bravo G, Brera B, Millan I, Dargallo J, Salmean J, and others. 1997. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. Clinica Puerta de Hierro Neural Transplantation Group. J Neurosurg 86(6):931-42.
178. Lotharius J, Dugan L, O'Malley K. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284-93.
179. Luskin MB. 1993. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron 11(1):173-89.
180. Ma Y, Fukuda M, Dhawan V, Shi Q, Greene P, Breeze R, and others. 2001. Dyskinesia following fetal cell transplantation for parkinsonism: a PET study. Ann Neurol, in press.
181. Macaya A, Munell F, Gubits R, Burke R. 1994. Apoptosis in substantia nigra following developmental striatal excitotoxic injury. Proc Natl Acad Sci U S A 91:8117-21.
182. Macklin R. 1999. The ethical problems with sham surgery in clinical research. N Engl J Med 341(13):992-6.
183. MacManus J, Hill I, Huang Z, Rasquinha I, Xue D, Buchan A. 1994. DNA damage consistent with apoptosis in transient focal ischemic neocortex. Neuroreport 5:493-6.
184. Madrazo I, León V, Torres C, Aguilera Md, Varela G, Alvarez F, and others. 1988. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 318:51.
185. Madrazo I, Franco-Bourland R, Aguilera M, Ostrosky-Solis F, Madrazo M, Cuevas C, and others. 1991. Autologous adrenal medullary, fetal mesencephalic, and fetal adrenal brain transplantation in Parkinson's disease: a long-term postoperative follow-up. J Neural Transplant Plast 2(3-4):157-64.
186. Mahalik TJ, Hahn WE, Clayton GH, Owens GP. 1994. Programmed cell death in developing grafts of fetal substantia nigra. Exp Neurol 129(1):27-36.
187. Mahowald MB, Areen J, Hoffer BJ, Jonsen AR, King P, Silver J, and others. 1987. Transplantation of neural tissue from fetuses. Science 235:1307-8.
188. Malorni W, Rivabene R, Santini M, Donelli G. 1993. N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells. Fed Eur Biochem Soc 327:75-8.
189. Mamelak AN, Eggerding FA, Oh DS, Wilson E, Davis RL, Spitzer R, and others. 1998. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J Neurosurg 89(4):592-8.
190. Mandel RJ, Brundin P, Björklund A. 1990. The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur J Neurosci 2:888-94.
191. Marchionini DM, Collier TJ, Camargo MD, McGuire SO, Pitzer MR, Sortwell CE. 2001. Extracellular matrix molecules tenascin and L1 improve dopaminergic graft survival. Exp Neurol 170:208.
192. Marconi R, Lefebvre-Caparros D, Bonnet A-M, Vidailhet M, Dubois B, Agid Y. 1994. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9(1):2-12.
193. Marti M, James C, Oo T, Kelly W, Burke R. 1997. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J Neurosci 17:2030-9.
194. Martinez-Serrano A, Snyder E. 1998. Neural stem cell lines for CNS repair. In: Tuszynski M, Kordower J, editors. CNS regeneration: basic science & clinical applications. San Diego (CA): Academic Press. p 203-50.
195. Mayo JC, Sainz KM, Antolin I, Rodriguez C. 1999. Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res 818(2):221-7.
196. McKay RD. 1989. The origins of cellular diversity in the mammalian central nervous system [Review]. Cell 58(5):815-21.
197. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, and others. 2000. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 92(5):863-9.
198. Mendez I, Hong M, Smith S, Dagher A, Desrosiers J. 2000. Neural transplantation cannula and microinjector system: experimental and clinical experience. Technical note. J Neurosurg 92(3):493-9.
199. Mendez I, Sadi D, Hong M. 1996. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci 16(22):7216-27.
200. Molenaar GJ, Hogenesch RI, Sprengers ME, Staal MJ. 1997. Ontogenesis of embryonic porcine ventral mesencephalon in the perspective of its potential use as a xenograft in Parkinson's disease. J Comp Neurol 382(1):19-28.
201. Molina H, Quinones-Molina R, Munoz J, Alvarez L, Alaminos A, Ortega I, and others. 1994. Neurotransplantation in Parkinson's disease: from open microsurgery to bilateral stereotactic approach: first clinical trial using microelectrode recording technique. Stereotact Funct Neurosurg 62(1-4):204-8.
202. Montoya CP, Astell S, Dunnett SB. 1990. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog Brain Res 82: 459-66.
203. Morihisa JM, Nakamura RK, Freed WJ, Mishkin M, Wyatt RJ. 1984. Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp Neurol 84:643-53.
204. Nagatsu T. 1991. Genes for human catecholamine-synthesizing enzymes. Neurosci Res 12:315-45.
205. Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, and others. 2001. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 50(2):181-7.
206. Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. 1994. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci U S A 91(26):12408-12.
207. Nakao N, Frodl EM, Widner H, Carlson E, Eggerding FA, Epstein CJ, and others. 1995. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease [see comments]. Nature Med 1(3):226-31.
208. Niijima K, Araki M, Ogawa M, Nagatsu I, Sato F, Kimura H, and others. 1990. Enhanced survival of cultured dopamine neurons by treatment with soluble extracts from chemically deafferentiated striatum of adult rat brain. Brain Res 528(1):151-4.
209. Nikkah G, Cunningham M, Jödicke A, Knappe U, Björklund A. 1994. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspentions in the rat Parkinson model. Brain Res 633:133-43.
210. Nikkhah G, Bentlage C, Cunningham MG, Bjorklund A. 1994. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci 14(6):3449-61.
211. Nikkhah G, Duan WM, Knappe U, Jodicke A, Bjorklund A. 1993. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 56(1):33-43.
212. Nosrat C, Tomac A, Lindqvist E, Lindskog S, Humpel C, Stromberg I, and others. 1996. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res 286:191-207.
213. Obeso JA, Rodriguez MC, Gorospe A, Guridi J, Alvarez L, Macias R. 1997. Surgical treatment of Parkinson's disease [Review]. Baillieres Clin Neurol 6(1):125-45.
214. Odorico JS, Kaufman DS, Thomson JA. 2001. Multilineage differentiation from human embryonic stem cell lines. Stem Cells 19(3):193-204.
215. Olanow CW. 1993. A radical hypothesis for neurodegeneration. Trends Neurosci 16:439-44.
216. Olanow CW, Freeman T, Kordower J. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 345(2):146; discussion 147.
217. Olanow CW, Freeman TB, Kordower JH. 1997. Neural transplantation as a therapy for Parkinson's disease. Adv Neurol 74:249-69.
218. Olson L. 1990. Grafts and growth factors in CNS. Basic science with clinical promise [Review]. Stereotactic Function Neurosurg 55:250-67.
219. Olson L, Seiger A. 1972. Brain tissue transplanted to the anterior chamber of the eye: 1. Fluorescence histochemistry of immature catecholamine and 5-hydroxytryptamine neurons reinnervating the rat iris. Z Zellforsch Mikrosh Anat 135:175-94.
220. Olson L, Seiger A. 1976. Locus coeruleus: fiber growth regulation in oculo. Med Biol 54:142-5.
221. Othberg A, Keep M, Brundin P, Lindvall O. 1997. Tirilazad mesylate improves survival of rat and human embyronic mesencephalic neurons in vitro. Exp Neurol 147:498-502.
222. Ourednik V, Ourednik J, Park KI, Teng YD, Aboody KA, Auguste KI, and others. 2000. Neural stem cells are uniquely suited for cell replacement and gene therapy in the CNS. Novartis Found Symp 231:242-62.
223. Palmer MR, Granholm AC, van Home CG, Giardina KE, Freund RK, Moorhead JW, and others. 2001. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats. Brain Res 890(1):86-99.
224. Park KI, Snyder EY. 2000. Injury shifts migrational patterns and promotes new neurons in "non-neurogenic" CNS regions. Nature in revision.
225. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. 1979. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204:643-53.
226. Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, and others. 1994. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117(Pt 3):487-99.
227. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, and others. 1999. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2(12):1137-40.
228. Pitzer MR, Sortwell CE, Daley BF, Collier TJ. 2000. Pre-injections of vascular endothhelial growth factor (VEGF) promotes graft- associated behavioral recovery. Exp Neurol 164:448.
229. Pitzer MR, Sortwell CE, McGuire SO, Daley BF, Collier TJ. 2001. Vascular endothelial growth factor (VEGF) improves survival of cultured mesencephalic dopamine neurons. Exp Neurol 170:203.
230. Poduslo JF, Curran GL. 1996. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT- 3, BDNF. Brain Res Mol Brain Res 36(2):280-6.
231. Quinn NP. 1990. The clinical application of cell grafting techniques in patients with Parkinson's disease [Review]. Prog Brain Res 82:619-25.
232. Raff M, Barres B, Burne J, Coles H, Ishizaki Y, Jacobson M. 1993. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262:695-700.
233. Rall WF, Wood MJ. 1994. High in vitro and in vivo survival of day 3 mouse embryos vitrified or frozen in a non-toxic solution of glycerol and albumin. J Reprod Fertil 101(3):681-8.
234. Redmond D Jr, Roth RH, Spencer DD, Naftolin F, Leranth C, Robbins RJ, and others. 1993. Neural transplantation for neurodegenerative diseases: past, present, and future [Review]. Ann N Y Acad Sci 695:258-66.
235. Redmond DE Jr, Freeman T 2001. The American Society for Neural Transplantation and Repair-considerations and guidelines for studies of human subjects. Cell Transplant 10(8):661-4.
236. Redmond DE Jr, Leranth C, Spencer DD, Robbins R, Vollmer T, Kim JH, and others. 1990. Fetal neural graft survival. Lancet ii:820-2.
237. Redmond DE Jr, Marek KL, Naftolin F, Leranth C, Robbins RJ, Bunney BS, and others. 1998. Outcome of fetal mesencephalic grafts placed into the striatum of 15 patients with Parkinsonism: site of placement and extended functional effects. Exp Neurol 153(2):373.
238. Redmond DE Jr, Naftolin F, Collier TJ, Leranth C, Robbins RJ, Sladek CD, and others. 1988. Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. Science 242(4879):768-71.
239. Redmond DE Jr, Ourednik J, Ourednik V, Roth RH, Elsworth JD, Sladek JR Jr, and others. 2000. Human neural stem cells survive, migrate, and differentiate into TH-Positive neurons in mesencephalon of adult MPTP-treated non-human primates. Exp Neurol 164:445.
240. Redmond DE Jr, Roth RH, Sladek JR. 1985. MPTP produces classic parkinsonian syndrome in African green monkeys. Neurosci Abstr 11(1):166.
241. Redmond DE Jr, Sladek JR Jr, Roth RH, Collier TJ, Elsworth JD, Deutch AY, and others. 1986a. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1(8490):1125-7.
242. Redmond DE Jr, Sladek JR Jr, Roth RH, Collier TJ, Elsworth JD, Deutch AY, and others. 1986b. Transplants of primate neurons [letter]. Lancet 2(8514):1046.
243. Redmond DE Jr, Sladek JR, Spencer DD. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 345(2):146-7.
244. Rehncrona S. 1997. A critical review of the current status and possible developments in brain transplantation. Adv Tech Stand Neurosurg 23:3-46.
245. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, and others. 1999. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 8(1-2):56-63.
246. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, and others. 1995. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 38(4):580-8.
247. Rosario CM, Yandava BD, Kosaras B, Zurakowski D, Sidman RL, Snyder EY. 1997. Differentiation of engrafted multipotent neural progenitors towards replacement of missing granule neurons in meander tail cerebellum may help determine the locus of mutant gene action. Development 124(21):4213-24.
248. Rosenblad C, Kirik D, Bjorklund A. 1999. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 10(8):1783-7.
249. Rosenblad C, Martinez-Serrano A, Bjorklund A. 1996. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75(4):979-85.
250. Rosenstein JM. 1995. Why do neural transplants survive? An examination of some metabolic and pathophysiological considerations in neural transplantation [Review]. Exp Neurol 133(1):1-6.
251. Rosenstein JM, Mani N, Silverman WF, Krum JM. 1998. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A 95:7086-91.
252. Roth JA. 1986. Sulfoconjugation: role in neurotransmitter and secretory protein activity. Trends Pharmacol Sci October:404-7.
253. Sanberg PR, Willing AE, Cahill DW. 2001. Neurosurgery for the 21st century. What does neurobiology justify for repairing neurodegenerative disorders? Clin Neurosurg 48:113-26.
254. Sanchez-Pernaute R, Studer L, Bankiewicz KS, Major EO, McKay RD. 2001. In vitro generation and transplantation of precursor- derived human dopamine neurons. J Neurosci Res 65(4):284-8.
255. Sautter J, Tseng JL, Braguglia D, Aebischer P, Spenger C, Seiler RW, and others. 1998. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 149(1):230-6.
256. Sawada H, Ibi M, Kihara T, Urushitani M, Nakanishi M, Akaike A, and others. 2000. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J Neurochem 74(3):1175-84.
257. Sawamoto K, Nakao N, Kakishita K, Ogawa Y, Toyama Y, Yamamoto A, and others. 2001. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 21(11):3895-903.
258. Sawle GV, Bloomfield PM, Bjorklund A, Brooks DJ, Brundin P, Leenders KL, and others. 1992. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 31(2):166-73.
259. Schaar D, Sieber B, Dreyfus C, Black I. 1993. Regional and cell- specific expression of GDNF in rat brain. Exp Neurol 124:368-71.
260. Schierle G, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. 1999. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Med 5:97-100.
261. Schultz W, Romo R. 1992. Role of primate basal ganglia and frontal cortex in the internal generation of movements: I. Preparatory activity in the anterior striatum. Exp Brain Res 91(3):363-84.
262. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, and others. 2000. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54(5):1042-50
263. Schwab RS, England AC Jr. 1969. Projection techniques for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson I, editors. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E. and S. Livingstone. p 152-7.
264. Shimazaki K, Urabe M, Monahan J, Ozawa K, Kawai N. 2000. Adeno-associated virus vector-mediated bcl-2 gene transfer into post- ischemic gerbil brain in vivo: prospects for gene therapy of ischemia-induced neuronal death. Gene Ther 7(14):1244-9.
265. Silverman W, Krum J, Mani N, Rosenstein J. 1998. Effects of VEGF on mesencephalic explants. Soc Neurosci Abstr 24:298.
266. Sinclair SR, Fawcett JW, Dunnett SB. 1999. Delayed implantation of nigral grafts improves survival of dopamine neurones and rate of functional recovery. Neuroreport 10(6):1263-7.
267. Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. 1996. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 7(15-17): 2547-52.
268. Sladek JR, Collier T, Bundock E, Roth RH, Elsworth JD, Taylor J, and others. 2001. Striatal grafts direct the growth of fibers from co-grafted and host dopaminergic neurons in monkey. Am Soc Neural Transplant Rep 8:34.
269. Sladek JR Jr, Collier TJ, Elsworth JD, Roth RH, Taylor JR, Redmond DE Jr. 1998. Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in non-human primates. Cell Transplant 7(2):87-96.
270. Sladek JR Jr, Collier TJ, Elsworth JD, Taylor JR, Roth RH, Redmond DE Jr. 1993. Can graft-derived neurotrophic activity be used to direct axonal outgrowth of grafted dopamine neurons for circuit reconstruction in primates? Exp Neurol 124:134-9.
271. Sladek JR Jr, Elsworth JD, Roth RH, Blanchard BC, Taylor JR, Collier TJ, and others. 1995. Co-grafts in dopamine-depleted primates: preliminary results and theoretical issues related to human applications for Parkinson's disease. In: Juurlink BHJ, editor. Neural cell specification, molecular mechanisms and neurotherapeutic implications. New York: Plenum Press. p 219-30.
272. Sladek JR Jr, Elsworth JD, Roth RH, Evans LE, Collier TJ, Cooper SJ, and others. 1993. Fetal dopamine cell survival after transplantation is dramatically improved at a critical donor gestational age in non-human primates. Exp Neurol 122(1):16-27.
273. Sladek JR Jr, Redmond DE Jr, Collier TJ, Blount JP, Elsworth JD, Taylor JR, and others. 1988. Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. Prog Brain Res 78:497-506.
274. Sladek JR Jr, Redmond DE Jr, Collier TJ, Haber SN, Elsworth JD, Deutch AY, and others. 1987. Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. Prog Brain Res 71:309-23.
275. Smith CB. 1984. Aging and changes in cerebral energy metabolism. Trends Neurosci (June):203-8.
276. Snyder E, Fisher L. 1996. Gene therapy in neurology. Curr Opin Pediatr 8:558-68.
277. Snyder E, Yoon C, Flax J, Macklis J. 1997. Multipotent neural progenitors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex. Proc Natl Acad Sci U S A 94:11645-50.
278. Snyder EY. 1995. Immortalized neural stem cells: insights into development; prospects for gene therapy and repair. Proc Assoc Am Phys 107(2):195-204.
279. Snyder EY, Macklis JD. 1995. Multipotent neural progenitor or stemlike cells may be uniquely suited for therapy for some neurodegenerative conditions. Clin Neurosci 3(5):310-6.
280. Snyder EY, Senut MC. 1997. The use of nonneuronal cells for gene delivery. Neurobiol Dis 4(2):69-102.
281. Sortwell CE, Camargo MD, Pitzer MR, Gyawali S, Collier TJ. 2001. Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval. Exp Neurol 169(1):23-9.
282. Sortwell C, Collier T, Sladek J Jr. 1998. Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons. J Comp Neurol 399:530-40.
283. Sortwell CE, Daley BF, Pitzer MR, McGuire SO, Sladek JR Jr, Collier TJ. 2000. Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J Comp Neurol 426(1):143-53.
284. Sortwell CE, Pitzer MR, Collier TJ. 2000. Time course of apoptotic cell death within mesencephalic cell suspension grafts: implications for improving grafted dopamine neuron survival. Exp Neurol 165(2):268-77.
285. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, and others. 1992. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of Parkinsonian patients: functional effects for 18 months. N Engl J Med 327(22):1541-8.
286. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR Jr. 1990. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 110:201-8.
287. Stefanis L, Burke RE, Greene LA. 1997. Apoptosis in neurodegenerative disorders. Curr Opin Neurol 10(4):299-305.
288. Steindler DA, Kadrie T, Fillmore H, Thomas LB. 1996. The subependymal zone: "brain marrow." Prog Brain Res 108:349-63.
289. Steller H. 1995. Mechanisms and genes of cellular suicide. Science 267:1445-9.
290. Stenevi U, Bjorklund A, Svendgaard NA. 1976. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Res 114(1):1-20.
291. Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, and others. 1993. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124:401-12.
292. Stromberg I, Tornqvist N, Johansson S, Bygdeman M, Almqvist PM. 2001. Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons. Microsc Res Tech 54(5):287-97.
293. Subramanian T. 2001. Cell transplantation for the treatment of Parkinson's disease. Semin Neurol 21(1):103-15.
294. Sullivan AM, Pohl J, Blunt SB. 1998. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 10(12):3681-8.
295. Suri C, McClain J, Thurston G, McDonald D, Zhou H, Oldmixon E, and others. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468-71.
296. Takayama H, Ray J, Raymon HK, Baird A, Hogg J, Fisher LJ, and others. 1995. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1(1):53-8.
297. Takeshima T, Johnston JM, Commissiong JW. 1994. Oligodendrocyte- type-2 astrocyte (O-2A) progenitors increase the survival of rat mesencephalic, dopaminergic neurons from death induced by serum deprivation. Neurosci Lett 166(2):178-82.
298. Taylor JR, Elsworth JD, Roth RH, Collier TJ, Sladek JR, Redmond DE Jr. 1990. Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. In: Richards SJ, Dunnett SB, editors. Progress in brain research. Amsterdam: Elsevier. p 543-59.
299. Taylor JR, Elsworth JD, Roth RH, Sladek JR Jr, Collier TJ, Redmond DE Jr. 1991. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Exp Brain Res 85(2):335-48.
300. Taylor JR, Elsworth JD, Sladek JR Jr, Collier TJ, Roth RH, Redmond DE Jr. 1995. Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. Cell Transplant 4(1):13-26.
301. Taylor JR, Elsworth JD, Sladek JR Jr, Roth RH, Redmond DE Jr. 1994. Behavioral effects of MPTP administration in the vervet monkey: a primate model of Parkinson's disease. In: Woodruff ML, Nonneman AJ, editors. Toxin-induced models of neurological disorders. New York: Plenum Press. p 139-74.
302. Thomas FT, Contreras JL, Bilbao G, Ricordi C, Curiel D, Thomas JM. 1999. Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation. Surgery 126(2):299-304.
303. Tomozawa Y, Appel SH. 1986. Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro. Brain Res 399(1):111-24.
304. Tseng JL, Aebischer P. 2000. Encapsulated neural transplants. Prog Brain Res 127:189-202.
305. Ungerstedt U, Arbuthnott GW. 1970. Quantitative recording of rotational behavior in rats after 6-hydroxy- dopamine lesions of the nigrostriatal dopamine system. Brain Res 24(3):485-93.
306. Van Wagtendonk-De Leeuw AM, Den Daas JH, Kruip TA, Rall WF. 1995. Comparison of the efficacy of conventional slow freezing and rapid cryopreservation methods for bovine embryos. Cryobiology 32(2):157-67.
307. Vescovi A, Snyder E. 1999. Establishment & properties of genetically & epigenetically propagated neural stem cell clones: plasticity in vitro & in vivo. Brain Pathol 9:569-98.
308. Vogel G. 2001. Parkinson's research. Fetal cell transplant trial draws fire. Science 291(5511):2060-1.
309. Waddington JL, O'Boyle KM. 1989. Drugs acting on brain dopamine receptors: a conceptual reevaluation five years after the first selective D1 antagonist. Pharmacol Ther 43:1-52.
310. Wagner J, Akerud P, Castro DS, Holm PC, Canals JM, Snyder EY, and others. 1999. Induction of a midbrain dopaminergic phenotype in Nurrl-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 17(7):653-9.
311. Waldmeier PC, Delini-Stula A, Maitre L. 1976. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg Arch Pharmacol 292:9-14.
312. Wang Y, Tien LT, Lapchak PA, Hoffer BJ. 1996. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res 286(2):225-33.
313. Watts C, Brasted PJ, Dunnett SB. 2000. The morphology, integration, and functional efficacy of striatal grafts differ between cell suspensions and tissue pieces. Cell Transplant 9(3):395-407.
314. Watts C, Caldwell MA, Dunnett SB. 1998. The development of intracerebral cell-suspension implants is influenced by the grafting medium. Cell Transplant 7(6):573-83.
315. Wennberg L, Czech KA, Larsson LC, Mirza B, Bennet W, Song Z, and others. 2001. Effects of immunosuppressive treatment on host responses against intracerebral porcine neural tissue xenografts in rats. Transplantation 71(12):1797-806.
316. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, and others. 1997. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42(1):95-107.
317. Whittemore SR, Snyder EY. 1996. Physiological relevance and functional potential of central nervous system-derived cell lines. Mol Neurobiol 12(1):13-38.
318. Wictorin K, Brundin P, Sauer H, Lindvall O, Bjorklund A. 1992. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats. J Comp Neurol 323(4):475-94.
319. Widenfalk J, Nosrat C, Tomac A, Westphal H, Hoffer B, Olson L. 1997. Neurturin and glial cell line-derived neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNF-alpha with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. J Neurosci 17:8506-19.
320. Widner H. 1994. NIH neural transplantation funding [letter]. Science 263(5148):737.
321. Widner H, Brundin P. 1988. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res 13:287-324.
322. Widner H, Rehncrona S. 1993. Transplantation and surgical treatment ofparkinsonian syndromes [Review]. Curr Opin Neurol Neurosurg 6(3):344-9.
323. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, and others. 1992. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) [see comments]. N Engl J Med 327(22): 1556-63.
324. Williams N. 2001. Setback spurs Parkinson's disease research. Curr Biol 11(8):R285-6.
325. Yandava BD, Billinghurst LL, Snyder EY. 1999. "Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci U S A 96(12):7029-34.
326. Yurek DM. 1997. Intranigral transplants of fetal ventral mesencephalic tissue attenuate D1-agonist-induced rotational behavior. Exp Neurol 143(1):1-9.
327. Yurek DM. 1998. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 153(2):195-202.
328. Yurek DM, Collier TJ, Sladek JR Jr. 1990. Embryonic mesencephalic and striatal co-grafts: development of grafted dopamine neurons and functional recovery. Exp Neurol 109:191-9.
329. Yurek DM, Steece-Collier K, Collier TJ, Sladek JR Jr. 1991. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp Brain Res 86:97-107.
330. Zabek M, Mazurowski W, Dymecki J, Stelmachow J, Gawur B, Trautsolt W, and others. 1992. Transplantation of fetal dopaminergic cells in Parkinson disease [Polish]. Neurologia I Neurochirurgia Polska 1:13-9.
331. Zawada WM, Zastrow DJ, Clarkson ED, Adams FS, Bell KP, Freed CR. 1998. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res 786(1-2):96-103.
332. Zhou J, Shen Y, Tang Z, Xu L, Bradford HF, Yu Y. 2000. Striatal extracts promote the survival and phenotypic expression of rat fetal dopaminergic neurons in vitro. Neurosci Lett 292(1):5-8.
333. Zurn AD, Tseng J, Aebischer P. 1996. Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps [Review]. Eur Neurol 36(6):405-8.